Stefano PEPE | Publications

53279Phase I-II study of xelox and bevacizumab plus erlotinib in sequential combination (XELO-TARAV) in first line colorectal cancer: Run in part.

	2007
	Abstract in rivista
	Phase I-II study of xelox and bevacizumab plus erlotinib in sequential combination (XELO-TARAV) in first line colorectal cancer: Run in part. ANNALS OF ONCOLOGY. Vol. 18. Pag.11-11 ISSN:0923-7534.
	G., Tortora; C., Carlomagno; R., Bianco; G., Daniele; Pepe, Stefano; D., Leopardo; R., Marciano; M., De Laurentiis; F., Ciardiello; S., De Placido
	Show it in Product Database (IRIS)

53271Cell growth-inhibition and cell cycle perturbations induced by a new synthetic iminoquinone, 5H-pyridophenoxazin-5-one, in human breast carcinoma cell lines.

	2007
	Abstract in rivista
	Cell growth-inhibition and cell cycle perturbations induced by a new synthetic iminoquinone, 5H-pyridophenoxazin-5-one, in human breast carcinoma cell lines. CYTOMETRY. PART A. Vol. 73A. Pag.60-60 ISSN:1552-4922.
	Fusciello, C.; Bolognose, A.; La Vecchia, A.; Ubezio, P.; Sabbatino, F.; Pepe, Stefano
	Show it in Product Database (IRIS)